VRDN
NASDAQ HealthcareViridian Therapeutics, Inc. - Common Stock
Biotechnology
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
�� 市场数据
| 价格 | $14.80 |
|---|---|
| 成交量 | 1,555,069 |
| 市值 | 1.51B |
| 贝塔系数 | 1.170 |
| RSI（14日） | 16.3 超卖 |
| 200日均线 | $24.46 |
| 50日均线 | $25.11 |
| 52周最高 | $34.29 |
| 52周最低 | $11.76 |
| Forward P/E | -6.32 |
| Price / Book | 2.55 |
🎯 投资策略评分
VRDN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (98/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 💰 Dividend Daddy (22/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 VRDN in your text
粘贴任何文章、记录或帖子 — 工具将提取 VRDN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.